LCT expands diabetes trial
Friday, 06 June, 2008
Living Cell Technologies (ASX: LCT) has decided to begin testing larger doses in its phase 1 clinical trial for type 1 diabetes.
In phase one of the trial, five patients were implanted with the lowest recommended dose of the company's DiabeCells, encapsulated insulin-producing cells sourced from pigs.
So far the patients have experienced no ill-effects, and have experienced a quantifiable reduction in the amount of insulin they require daily.
Both the number of patients and the dosage they receive has been doubled over the previous trial, with 10 patients receiving the double dose.
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
Portable point-of-care test detects four common STIs in under an hour
Australian researchers have developed a portable point-of-care test that detects four common...
AusBiotech and Proto Axiom partner on investor-focused life sciences programs
AusBiotech and Proto Axiom have announced a partnership to strengthen national coordination...
